Sign In
Buy GPCR
$48.04
-1.43 (-2.89%)
At Close: Jul 31, 2026
Should You Still Buy the Nasdaq's Best-Performing October Stocks?
05:20am, Friday, 03'rd Nov 2023
Structure Therapeutics' weight-loss drug candidate is attracting attention over excitement about obesity treatments. ImmunityBio rallied on hopes that its bladder cancer drug will now be better unders
Structure Therapeutics (GPCR) Stock Up 9% This Week: Here's Why
09:46am, Friday, 06'th Oct 2023
Structure Therapeutics (GPCR) rises 9% on encouraging initial data from the early-stage study of its pipeline candidate, GSBR-1290, in healthy overweight or obese individuals.
Structure Therapeutics: Tipping The Scales In Obesity Management
11:28pm, Tuesday, 03'rd Oct 2023
Structure Therapeutics' oral small molecule GLP-1, GSBR-1290, has shown promising results in Phase 1b studies, surpassing competitor benchmarks for weight loss. GSBR-1290 demonstrated potential effica
Why Shares of Structure Therapeutics Are Up Monday
03:48pm, Monday, 02'nd Oct 2023
Analysts upgraded their price targets for Structure Therapeutics. The company's obesity therapy can be taken as a once-daily pill.
Final Trades: Rivian, Pfizer, Treasury Bonds and more
06:26pm, Friday, 29'th Sep 2023
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Structure Therapeutics stock soars on positive weight loss data
12:55pm, Friday, 29'th Sep 2023
Structure Therapeutics Inc shares surged 34% to $50.34 in midday trading on Friday after the clinical-stage global biopharmaceutical company announced what it called positive results of the Phase 1b m
Why Shares of Structure Therapeutics Are Soaring on Friday
12:50pm, Friday, 29'th Sep 2023
Structure's weight-loss drug candidate is of the same class as Mounjaro and Wegovy, but while those drugs must be injected, Structure's is taken orally. Structure has also entered into a private stock
Shares of biotech startup Structure Therapeutics surge more than 30% on promising obesity pill data
12:02pm, Friday, 29'th Sep 2023
Structure's pill is part of the same class of drugs as Novo Nordisk's blockbuster diabetes drug Ozempic and weight loss counterpart Wegovy.
Structure Therapeutics surges on promising early stage obesity drug data
10:15am, Friday, 29'th Sep 2023
Shares of Structure Therapeutics soared 60% on Friday after the drug developer's oral obesity treatment succeeded in a small early-stage study.
Structure Therapeutics shares surge after positive results in weight-loss trial, $300 million private placement
08:02am, Friday, 29'th Sep 2023
Structure Therapeutics Inc.'s American depositary receipts GPCR, +4.96% jumped more than 90% premarket on Friday after the company announced positive results from an early-stage trial of a weight-loss
U.S. IPO Weekly Recap: July Closes Out With 2023's First Direct Listing And A Wave Of Small IPOs
06:15am, Saturday, 29'th Jul 2023
U.S. IPO Weekly Recap: July Closes Out With 2023's First Direct Listing And A Wave Of Small IPOs
As Ozempic/Wegovy frenzy continues, Morgan Stanley lifts forecasts for weight-loss drugs to $77 billion
05:05am, Friday, 21'st Jul 2023
Morgan Stanley on Friday lifted its forecast for annual sales of weight-loss drugs to $77 billion, as patient demand for the medicines has outstripped supply and been fueled by a social-media frenzy.
IPO Round Up of First Half of 2023
12:17pm, Wednesday, 05'th Jul 2023
Normally, IPO activity gains momentum in the second quarter and peaks in June. This year was no exception.
Why Shares of Structure Therapeutics Rose Monday
09:05pm, Monday, 26'th Jun 2023
The clinical-stage biotech's lead therapy is designed to treat diabetes and obesity. Structure has enough cash, it said, to fund operations through 2025.
This Biotech Is Developing The Next Ozempic. Should You Buy It?
08:00am, Friday, 16'th Jun 2023
Structure Therapeutics is working on therapies for diabetes and obesity. Its efforts are still early-stage, but it has plenty of cash to keep going.
